Radiation Toxicity Treatment Market Report 2026

The radiation toxicity treatment market size has grown strongly in recent years. It will grow from $3.98 billion in 2025 to $4.23 billion in 2026 at a compound annual growth rate (CAGR) of 6.4%. The growth in the historic period can be attributed to increased use of radiation in medical treatments, rising incidence of nuclear and radiation exposure risks, government stockpiling of radiation countermeasures, expansion of oncology radiotherapy applications, advancements in hematopoietic support therapies.

The radiation toxicity treatment market size is expected to see strong growth in the next few years. It will grow to $5.37 billion in 2030 at a compound annual growth rate (CAGR) of 6.1%. The growth in the forecast period can be attributed to growing investments in advanced radiation countermeasures, rising demand for rapid-response radiation treatments, expansion of personalized radiation toxicity management, increased focus on long-term survivorship care, ongoing clinical research into novel radioprotective agents. Major trends in the forecast period include increasing development of targeted radioprotective therapies, rising use of colony stimulating factors in treatment protocols, growing focus on bone marrow recovery solutions, expansion of emergency radiation preparedness treatments, enhanced clinical management of acute radiation syndrome.

The growing prevalence of cancer is expected to drive the growth of the radiation toxicity treatment market in the coming years. Cancer is a group of diseases marked by the uncontrolled growth and multiplication of abnormal cells that can invade nearby tissues and spread to other parts of the body. The rising prevalence of cancer is linked to factors such as lifestyle changes, environmental pollution, genetic susceptibility, and improved diagnostic techniques that enable earlier detection. Radiation toxicity treatment plays a critical role in managing the side effects associated with radiation therapy in cancer care, supporting patient recovery and reducing long-term health complications. For instance, in August 2024, according to a report published by Macmillan Cancer Support, a UK-based charitable organization, more than 3 million people were living with cancer in the UK, with projections indicating an increase to 3.5 million by 2025, 4 million by 2030, and 5.3 million by 2040. Therefore, the increasing prevalence of cancer is contributing to the expansion of the radiation toxicity treatment market.

Major companies operating in the radiation toxicity treatment market are emphasizing technological advancements such as advanced drug delivery systems to enhance treatment precision and effectiveness, improve patient adherence, and reduce side effects, ultimately supporting better therapeutic outcomes and faster recovery. Drug delivery systems are methods designed to transport medications to targeted areas of the body, ensuring accurate dosing and improved efficacy while minimizing unintended effects. For example, in December 2023, Coherus BioSciences, a US-based biopharmaceutical company, announced that the US Food and Drug Administration approved UDENYCA ONBODY, an on-body injector for pegfilgrastim-cbqv. This device is intended for use following chemotherapy to help lower the risk of infection caused by febrile neutropenia. It administers the medication within five minutes and includes a retractable needle to enhance safety and patient comfort. With this approval, Coherus aims to offer a more convenient and patient-friendly solution for managing chemotherapy-related side effects.

In June 2024, AstraZeneca Plc, a UK-based pharmaceutical company, acquired Fusion Pharmaceuticals Inc. for $2.5 billion. This acquisition is intended to strengthen AstraZeneca’s oncology portfolio by incorporating advanced radiopharmaceuticals such as FPI-2265, enhancing research and manufacturing capabilities, and accelerating the transition toward targeted cancer therapies while expanding its presence in Canada. Fusion Pharmaceuticals Inc. is a Canada-based biotechnology company focused on developing next-generation radiopharmaceuticals as precision oncology treatments.

Major companies operating in the radiation toxicity treatment market are Pfizer Inc., Merck And Co Inc., Bayer AG, Sanofi S.A., Bristol Myers Squibb Company, AstraZeneca PLC, Novartis AG, Amgen Inc., Recipharm AB, Coherus BioSciences Inc., Eckert And Ziegler Strahlen Und Medizintechnik AG, Theragenics Corp., NorthStar Medical Radioisotopes LLC, Fusion Pharmaceuticals Inc., Partner Therapeutics Inc., Heyl Chemisch pharmazeutische Fabrik GmbH And Co KG, Humanetics Corporation, Actinium Pharmaceuticals Inc., Clarity Pharmaceuticals Ltd., Emergent BioSolutions Inc., Bavarian Nordic A S, BTG International Ltd., Jubilant Radiopharma, Cardinal Health Inc.

North America was the largest region in the radiation toxicity treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the radiation toxicity treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the radiation toxicity treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the radiation toxicity treatment market by increasing costs of imported active pharmaceutical ingredients, biologics manufacturing inputs, sterile packaging materials, and specialized medical devices used in radiation countermeasure production. Healthcare systems and research institutes in North America and Europe are most affected due to reliance on global pharmaceutical supply chains, while Asia-Pacific faces higher production costs for generic formulations. These tariffs are increasing procurement costs and extending approval timelines. However, they are also encouraging domestic drug manufacturing, localized API production, and strengthened national preparedness programs for radiation emergencies.

The radiation toxicity treatment market research report is one of a series of new reports that provides radiation toxicity treatment market statistics, including radiation toxicity treatment industry global market size, regional shares, competitors with a radiation toxicity treatment market share, detailed radiation toxicity treatment market segments, market trends and opportunities, and any further data you may need to thrive in the radiation toxicity treatment industry. This radiation toxicity treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Radiation toxicity treatment includes medical strategies aimed at managing and reducing the harmful effects caused by excessive exposure to radiation. These treatments focus on alleviating symptoms such as fatigue, nausea, and skin damage, as well as addressing more severe complications including organ injury or bone marrow damage, with the objective of supporting recovery and minimizing long-term health risks.

The primary products in the radiation toxicity treatment market include colony-stimulating factors, potassium iodide, prussian blue, diethylenetriamine pentaacetic acid, and other agents. Colony-stimulating factors are biological substances that stimulate bone marrow activity to increase the production of blood cells and are essential for restoring blood cell counts in conditions associated with low blood levels, such as those occurring during certain medical treatments. These therapies are indicated for conditions such as acute radiation syndrome and chronic radiation syndrome and are used to address both ionizing and non-ionizing radiation exposure. Radiation toxicity treatments are utilized in hospitals as well as research and academic institutions.

The radiation toxicity treatment market includes revenues earned by entities by providing services such as blood transfusions, chelation therapy, skin care and burn management, cancer screening, pain management, and bone marrow protection. The market value includes the value of related goods sold by the service provider or included within the service offering. The radiation toxicity treatment market consists of sales of radiation detection and survey devices, personal dosimeters, linear accelerators (LINACs), and neutron capture therapy systems. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.